NS Partners Ltd Has $13.12 Million Stock Position in Johnson & Johnson (NYSE:JNJ)

NS Partners Ltd reduced its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 5.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 80,955 shares of the company's stock after selling 4,393 shares during the quarter. NS Partners Ltd's holdings in Johnson & Johnson were worth $13,120,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Sachetta LLC raised its stake in Johnson & Johnson by 11.8% in the third quarter. Sachetta LLC now owns 7,599 shares of the company's stock valued at $1,232,000 after purchasing an additional 802 shares in the last quarter. Segall Bryant & Hamill LLC bought a new position in shares of Johnson & Johnson in the 3rd quarter worth $5,883,000. Prospera Private Wealth LLC boosted its stake in shares of Johnson & Johnson by 948.6% in the third quarter. Prospera Private Wealth LLC now owns 52,293 shares of the company's stock worth $8,475,000 after buying an additional 47,306 shares during the last quarter. Premier Fund Managers Ltd acquired a new stake in shares of Johnson & Johnson during the 3rd quarter worth about $7,982,000. Finally, Kraft Davis & Associates LLC increased its stake in Johnson & Johnson by 12.2% in the third quarter. Kraft Davis & Associates LLC now owns 2,592 shares of the company's stock valued at $416,000 after purchasing an additional 281 shares during the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Stock Up 0.1 %

Shares of Johnson & Johnson stock traded up $0.11 during trading on Wednesday, reaching $153.11. The company's stock had a trading volume of 7,315,274 shares, compared to its average volume of 7,026,197. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $168.85. The company has a market cap of $368.63 billion, a price-to-earnings ratio of 22.09, a P/E/G ratio of 2.74 and a beta of 0.53. The company has a 50-day simple moving average of $160.83 and a two-hundred day simple moving average of $156.19. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.21 by $0.21. The business had revenue of $22.47 billion during the quarter, compared to analysts' expectations of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The company's revenue for the quarter was up 5.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.66 EPS. As a group, equities analysts forecast that Johnson & Johnson will post 9.93 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be issued a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.24%. The ex-dividend date is Tuesday, November 26th. Johnson & Johnson's dividend payout ratio is 71.78%.

Insider Activity at Johnson & Johnson

In other news, VP Robert J. Decker sold 5,635 shares of the business's stock in a transaction on Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the sale, the vice president now directly owns 18,973 shares of the company's stock, valued at approximately $3,131,683.38. The trade was a 22.90 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.16% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several analysts recently issued reports on the stock. Daiwa Capital Markets cut shares of Johnson & Johnson from an "outperform" rating to a "neutral" rating and cut their price target for the company from $160.00 to $150.00 in a report on Tuesday, July 23rd. Citigroup lifted their target price on Johnson & Johnson from $180.00 to $185.00 and gave the company a "buy" rating in a research report on Wednesday, October 16th. Wells Fargo & Company increased their price objective on Johnson & Johnson from $163.00 to $166.00 and gave the company an "equal weight" rating in a research note on Wednesday, October 16th. Daiwa America cut Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a report on Tuesday, July 23rd. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $215.00 price target on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Seven investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $175.94.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.